Drugs / 5,6-Dimethylxanthenone-4-acetic acid
5,6-Dimethylxanthenone-4-acetic acid
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00856336 | May 2003 → Jan 2004 | refractory malignant neoplasm | Antisoma Research | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 5,6-Dimethylxanthenone-4-acetic acid | “5,6-Dimethylxanthenone-4-acetic acid (DMXAA, ASA404), an antitumor vascular-disrupting agent in phase I clinical trials.” PMID 19387077 ↗ Apr 2009 |
| Known as | ASA404 | “5,6-Dimethylxanthenone-4-acetic acid (DMXAA, ASA404), an antitumor vascular-disrupting agent in phase I clinical trials.” PMID 19387077 ↗ Apr 2009 |
| Known as | DMXAA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00856336 ↗ |
| Action | Inhibit | “In vitro studies showed nonspecific phosphodiesterase inhibition by DMXAA.” PMID 19387077 ↗ Apr 2009 |
| Route | Intravenous | “DMXAA, given intravenously over 20 minutes.” NCT00856336 ↗ |